BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10602338)

  • 1. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
    Pickavance LC; Tadayyon M; Widdowson PS; Buckingham RE; Wilding JP
    Br J Pharmacol; 1999 Dec; 128(7):1570-6. PubMed ID: 10602338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
    Pickavance LC; Buckingham RE; Wilding JP
    Diabetes Obes Metab; 2001 Jun; 3(3):171-80. PubMed ID: 11412281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
    Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
    Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
    Finegood DT; McArthur MD; Kojwang D; Thomas MJ; Topp BG; Leonard T; Buckingham RE
    Diabetes; 2001 May; 50(5):1021-9. PubMed ID: 11334404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
    Törüner F; Akbay E; Cakir N; Sancak B; Elbeg S; Taneri F; Aktürk M; Karakoç A; Ayvaz G; Arslan M
    Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
    Liu YL; Sennitt MV; Hislop DC; Crombie DL; Heyman RA; Cawthorne MA
    Int J Obes Relat Metab Disord; 2000 Aug; 24(8):997-1004. PubMed ID: 10951538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.
    Wang Q; Dryden S; Frankish HM; Bing C; Pickavance L; Hopkins D; Buckingham R; Williams G
    Br J Pharmacol; 1997 Dec; 122(7):1405-10. PubMed ID: 9421288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
    Cai XJ; Lister CA; Buckingham RE; Pickavance L; Wilding J; Arch JR; Wilson S; Williams G
    Brain Res Mol Brain Res; 2000 Apr; 77(1):131-7. PubMed ID: 10814839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats.
    Naderali EK; Pickavance LC; Wilding JP; Doyle PJ; Williams G
    Eur J Pharmacol; 2001 Mar; 416(1-2):133-9. PubMed ID: 11282122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.
    Yang C; Chang TJ; Chang JC; Liu MW; Tai TY; Hsu WH; Chuang LM
    Diabetes; 2001 Nov; 50(11):2598-602. PubMed ID: 11679440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
    Oakes ND; Thalén PG; Jacinto SM; Ljung B
    Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
    Sundaresan A; Radhiga T; Pugalendi KV
    J Physiol Biochem; 2016 Jun; 72(2):345-52. PubMed ID: 27090933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
    Livingstone DE; Kenyon CJ; Walker BR
    J Endocrinol; 2000 Dec; 167(3):533-9. PubMed ID: 11115781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet.
    Clegg DJ; Benoit SC; Reed JA; Woods SC; Dunn-Meynell A; Levin BE
    Am J Physiol Regul Integr Comp Physiol; 2005 Apr; 288(4):R981-6. PubMed ID: 15604298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.
    Gao W; Jusko WJ
    J Pharmacol Exp Ther; 2012 Jun; 341(3):617-25. PubMed ID: 22378938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
    Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
    Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
    Berthiaume M; Sell H; Lalonde J; Gélinas Y; Tchernof A; Richard D; Deshaies Y
    Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
    Carey DG; Cowin GJ; Galloway GJ; Jones NP; Richards JC; Biswas N; Doddrell DM
    Obes Res; 2002 Oct; 10(10):1008-15. PubMed ID: 12376581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.